lorvotuzumab mertansine + lenalidomide + dexamethasone

A combination therapy composed of **lorvotuzumab mertansine** (an antibody-drug conjugate targeting CD56), **lenalidomide** (an immunomodulatory agent), and **dexamethasone** (a synthetic glucocorticoid corticosteroid), under clinical investigation for relapsed or refractory multiple myeloma. - Lorvotuzumab mertansine (IMGN901) is an ADC consisting of a humanized anti-CD56 monoclonal antibody (lorvotuzumab/huN901) linked via disulfide bonds to the cytotoxin DM1, a maytansinoid that disrupts microtubules, leading to apoptosis of CD56+ malignant cells. - Lenalidomide enhances immune system function, modulates cytokine production, and has antiangiogenic activity, but its mechanisms also include direct antiproliferative effects. - Dexamethasone is a corticosteroid, broadly immunosuppressive and pro-apoptotic in lymphoid cells, used to reduce inflammation and as a component of anti-myeloma regimens. The combination is designed to harness the synergistic cytotoxicity of an ADC with immunomodulation and steroid potentiation in multiple myeloma settings where CD56 is commonly expressed[1][5].

Other names

huN901-DM1 + lenalidomide + dexamethasonelorvotuzumab mertansine + lenalidomide + dexamethasone